The U.S. Has Embraced Immigrant Tech Entrepreneurs. Now It's Europe's Turn

The U.S. Has Embraced Immigrant Tech Entrepreneurs. Now It's Europe's Turn

3 years ago
Anonymous $RGO3jP_V_c

https://www.scientificamerican.com/article/the-u-s-has-embraced-immigrant-tech-entrepreneurs-now-its-europes-turn/

The world is on the cusp of a counterattack on COVID thanks to several vaccines that are currently seeking regulatory approval and a swift rollout. For entrepreneurs and the tech industry, this is a moment when their value to society is demonstrated: business and technology is (along with medicine) leading us out of the pandemic.

But Germany’s Turkish community, and Europe’s minorities in general, are celebrating for a different reason. Turkish-Germans are an often marginalized group, similar to other minorities around the world. Like any community, they are proud of their success stories, such as Ugur Sahin and Özlem Türeci, the husband-and-wife co-founders of BioNTech, the firm behind the first vaccine to report a successful phase three trial, based on cutting edge mRNA technology.

The U.S. Has Embraced Immigrant Tech Entrepreneurs. Now It's Europe's Turn

Dec 2, 2020, 2:38pm UTC
https://www.scientificamerican.com/article/the-u-s-has-embraced-immigrant-tech-entrepreneurs-now-its-europes-turn/ > The world is on the cusp of a counterattack on COVID thanks to several vaccines that are currently seeking regulatory approval and a swift rollout. For entrepreneurs and the tech industry, this is a moment when their value to society is demonstrated: business and technology is (along with medicine) leading us out of the pandemic. > But Germany’s Turkish community, and Europe’s minorities in general, are celebrating for a different reason. Turkish-Germans are an often marginalized group, similar to other minorities around the world. Like any community, they are proud of their success stories, such as Ugur Sahin and Özlem Türeci, the husband-and-wife co-founders of BioNTech, the firm behind the first vaccine to report a successful phase three trial, based on cutting edge mRNA technology.